Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

  title={Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages},
  author={Jennifer L. Guerriero and Alaba Sotayo and Holly E. Ponichtera and Jessica A. Castrillon and Alexandra L. Pourzia and Sara E Schad and Shawn F. Johnson and Ruben D Carrasco and Suzan Lazo and Roderick T Bronson and Scott P. Davis and Mercedes Lobera and Michael A. Nolan and Anthony G. Letai},
Although the main focus of immuno-oncology has been manipulating the adaptive immune system, harnessing both the innate and adaptive arms of the immune system might produce superior tumour reduction and elimination. Tumour-associated macrophages often have net pro-tumour effects, but their embedded location and their untapped potential provide impetus to discover strategies to turn them against tumours. Strategies that deplete (anti-CSF-1 antibodies and CSF-1R inhibition) or stimulate… 

HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression

Combining low-dose TSA with anti-PD-L1 in this model significantly enhanced the durability of tumor reduction and prolonged survival of tumor-bearing mice, compared with the effect of either treatment alone, introducing HDAC inhibition as a potential means to harness the anti-tumor potential of macrophages in cancer therapy.

Macrophage targeting: opening new possibilities for cancer immunotherapy

Several animal studies suggest that tumour‐infiltrating myeloid cells, especially TAM, are one of the key targets to improve the efficacy of immunotherapies as these cells can suppress the functions of CD8+ T and NK cells.

Harnessing class II histone deacetylases in macrophages to combat breast cancer

Data is provided supporting the notion that rendering tumor-associated macrophages to display anti-tumorigenic activities may be beneficial, and the rationale to test the hypothesis that class IIa HDAC inhibition will promote an anti-Tumor innate immune response is provided.

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy

The ability of rationally engineered drug–nanoparticle combinations to efficiently modulate tumour-associated macrophages for cancer immunotherapy is demonstrated and R848, an agonist of the toll-like receptors TLR7 and TLR8 identified in a morphometric-based screen, is a potent driver of the M1 phenotype in vitro.

HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients

The data show that HDAC7 is an actionable driver of resistance to therapeutic antibodies by MDMs derived from CLL patients, and it is reported that TMP195 enhances phagocytic responses to antibody-opsonised CLL cells and E. coli within 30 min of treatment.

Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.

It is demonstrated that macrophages are the predominant infiltrating immune cell type in BRCA-associated TNBC and that combined PARP inhibition and macrophage targeting therapy induces a durable reprogramming of the tumor microenvironment, thus constituting a promising therapeutic strategy for TNBC.

Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing

The current knowledge on strategies able to reprogram TAMs with single as well as combination therapies is summarized and a shift eventually leads to the reconstitution of a reactive immune landscape able to destroy the tumor is summarized.

Targeting macrophages: therapeutic approaches in cancer

The state of the art of TAM-targeting strategies is evaluated, focusing on the limitations and potential side effects of the different therapies such as toxicity, rebound effects and compensatory mechanisms.

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy

The ability of rationally engineered drug–nanoparticle combinations to efficiently modulate TAMs for cancer immunotherapy is demonstrated, demonstrated by the administration of CDNP-R848 in multiple tumour models in mice, leading to controlled tumour growth and protecting the animals against tumour rechallenge.

Macrophages as tools and targets in cancer therapy

The molecular mechanisms underlying the reprogramming of macrophages in the tumour microenvironment are discussed and an overview ofmacrophage-targeted therapies for the treatment of cancer is provided.



CSF-1R inhibition alters macrophage polarization and blocks glioma progression

The results identify TAMs as a promising therapeutic target for proneural gliomas and establish the translational potential of CSF-1R inhibition for GBM.

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

Blockade of pathways mediating macrophage recruitment, in combination with chemotherapy, significantly decreases primary tumor progression, reduces metastasis, and improves survival by CD8+ T-cell-dependent mechanisms, thus indicating that the immune microenvironment of tumors can be reprogrammed to instead foster antitumor immunity and improve response to cytotoxic therapy.

Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression

Treatment of cervical carcinoma in mouse models with synthetic long peptide (SLP) vaccines induced influx of cytokine-producing CD8 T cells that strongly altered the numbers and phenotype of intratumoral macrophages, showing that therapeutic peptide vaccination could induce cytokin-producing T cells with strong macrophage-skewing capacity necessary for tumor shrinkage.

Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment

This study examined whether neutralizing CD11b monoclonal antibodies could inhibit the recruitment of myeloid cells into irradiated tumors and inhibit their regrowth and supported the rationale of using clinically available Mac-1 (CD11b/CD18) antibodies as an adjuvant therapy to radiotherapy.

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

These findings demonstrate a CD40-dependent mechanism for targeting tumor stroma in the treatment of cancer and demonstrate that cancer immune surveillance does not necessarily depend on therapy-induced T cells; rather, it is shown that tumor regression required macrophages but not T cells or gemcitabine.

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

All human solid tumor cells require CD47 expression to suppress phagocytic innate immune surveillance and elimination, showing that CD47 is a commonly expressed molecule on all cancers, its function to blockphagocytosis is known, and blockade of its function leads to tumor cell phagcytosis and elimination.

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy.

It is found that antibody-dependent phagocytosis by macrophages is a prominent mechanism for removal of tumor cells from the circulation in a murine tumor cell opsonization model and may help to optimize mAb therapeutic strategies for patients with cancer by helping to enhance macrophage recruitment and activity.

CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis

The mechanistic link between CCL2 expression and macrophage infiltration are correlated with poor prognosis and metastatic disease in human breast cancer and the origin of these macrophages is defined by showing that Gr1-positive inflammatory monocytes are preferentially recruited to pulmonary metastases but not to primary mammary tumours in mice.

The cellular and molecular origin of tumor-associated macrophages

In mice, mammary tumor growth induces the accumulation of tumor-associated macrophage that are phenotypically and functionally distinct from mammary tissue macrophages, which reveal the ontogeny of TAMs and a discrete tumor-elicited inflammatory response, which may provide new opportunities for cancer immunotherapy.